December 9th, 2020, 10:00 am PT / Category: Interviews
Surgically Targeted Radiation Therapy (STaRT): why the next big thing in brain tumor treatment is something small.
Mr Likens is an accomplished leader in the medical device industry. Prior to coming to GT Medical Technologies, he served as the president and chief executive officer of Ulthera, Inc. There, he led the startup from pre-commercialization to more than $100M in revenue and a $600M acquisition by Merz Pharma GmbH.
Mr Likens’ professional career began with Johnson & Johnson. However, he spent the bulk of his career at Baxter Healthcare Corporation, where he progressed through a variety of domestic and international sales, marketing, and general management roles that ultimately culminated in the position of president of Baxter Biotech North America, and then the president of its US Renal Care division.
Mr Likens is a member of the Greater Phoenix Economic Council Healthcare Innovation Committee and the City of Mesa Economic Development Advisory Board, as well as a member of the Kent State University College of Business Advisory Board. Mr Likens was awarded the 2019 Distinguished Alumni Award by his alma mater, Kent State University. He joined GT Medical Technologies because he was inspired by the company’s powerful purpose of “Improving the lives of patients with brain tumors.”
